AndhraNews.net
Home » Business News » 2013 » July » July 11, 2013

Implant Sciences to Exhibit at National Center for Spectator Sports Safety and Security Conference


July 11, 2013 - Wilmington, MA

Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it will exhibit its Quantum Sniffer™ QS-H150 handheld explosives trace detector and its Quantum Sniffer QS-B220 desktop explosives and drugs trace detector at the National Center for Spectator Sports Safety and Security (NCS4)'s fourth annual conference and exhibition on July 16th through 18th, 2013 in Orlando, Florida at booth #520.

The NCS4 conference focuses solely on the sports safety and security industry, emphasizing the need to share global knowledge and perspectives. The gathering of top professionals in the field will provide an environment dedicated to security and safety technologies, products, services, and education for safeguarding assets and spectators.

Implant Sciences' Quantum Sniffers have been used to provide security at some of the highest profile sporting events in the world including the 2008 Beijing Olympics, the 2011 Summer Universiade Games in Shenzhen, China, and the 2012 Special Olympics in London.

"Spectator sports security is an area of growing concern. Our systems uniquely offer fast, non-invasive, and radiation-free scanning of people, parcels, and event tickets," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "Logistically, within the framework of large scale sporting venues, our Quantum Sniffers provide security in a way that is feasible and cost-effective."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About the Quantum Sniffer™ QS-B220 Desktop Explosives and Drugs Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

MarketWire

Comment on this story

Share